Subscribe to Newsletter
Subspecialties Retina

No Further PRoblems

Credit: Image sourced from

Like trying to extinguish a gasoline fire with water, sometimes our best efforts to make things better end up making things far worse. Because of its prevention of proliferation, vascular permeability and neovascularization, the humanized, anti-vascular endothelial growth factor A (VEGF-A) prophylactic, ranibizumab (PR), is used as a treatment for age-related macular degeneration (AMD), specifically the more severe neovascular or exudative AMD (nAMD). Although its mechanism of action has been demonstrated, the question still stands: what effect does it have on the anatomical structures of the retina? Is it only doing what we expect, or is it causing unforeseen problems?

“Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration” is a new study published in ARVO’s Translational Vision Science & Technology and conducted by a research group from an American multi-institutional team (1). In this study, researchers compared the eyes of patients with intermediate age-related macular degeneration (AMD) that had been injected with PR every three months, with those given a sham injection. Over the course of 24 months, the researchers determined the effect of PR on drusen volume, macular layer thicknesses, and the progression of geographic atrophy (GA) area over 24 months in the PREVENT trial.

The results showed that PR given every three months did not appear to worsen the progressive retinal degenerative process as there were no statistical differences between the groups in anatomic parameters including drusen area and volume, macular thinning, or geographic atrophy progression in the eyes of patients with intermediate AMD. As the researchers concluded, “Our results have shown that this progressive retinal degenerative process was not worsened by quarterly dosing of ranibizumab in these eyes at risk for vision loss. Future studies with a more robust sample size and longer follow-up time may provide confirmation of the outcomes shown in this study and may elucidate additional relevant information on this topic.”

Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. CK Chan et al., “Impact of Prophylactic Ranibizumab to Prevent Neovascular Age-Related Macular Degeneration on Eyes With Intermediate Age-Related Macular Degeneration,” Transl Vis Sci Technol, 12, 1 (2023). PMID: 3765644
About the Author
Oscelle Boye

Associate Editor, The Ophthalmologist

I have always been fascinated by stories. During my biomedical sciences degree, though I enjoyed wet lab sessions, I was truly in my element when sitting down to write up my results and find the stories within the data. Working at Texere gives me the opportunity to delve into a plethora of interesting stories, sharing them with a wide audience as I go.

Related Product Profiles
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Subspecialties Retina
ForeseeHome® – remote monitoring to help detect wet AMD earlier and improve outcomes

| Contributed by Notal Vision

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: